Business Context and Reporting Period
SelectQuote, Inc. (SLQT) filed a Form 8-K on February 28, 2025, reporting the closing of a material definitive agreement involving the sale of Senior Non-Convertible Preferred Stock and warrants. The transaction was executed with NL Monarch Holdings LLC (Morgan Stanley) and NL Monarch Holdings II LLC (Bain Capital), collectively referred to as the Lead Investors.
Key Financial Metrics and Transaction Details
- Total Investment: $350,000,000 in cash.
- Preferred Stock Issued: 350,000 shares with a face value of $1,000 per share ($350 million aggregate).
- Warrants Issued: 30,833,333 warrants to purchase common stock, split into three tranches with varying exercise prices.
- Dividend Rate: Initial rate of 14.5% per annum, payable quarterly. The rate may decrease to 13.5% if specific liquidity and leverage targets are met, or increase by 2% per annum upon a "Preferred Default."
- Closing Fees: The Company paid an aggregate closing fee of 3.0% of the aggregate purchase price to the Purchasers.
- Redemption Terms: The Company may redeem up to 50,000 shares between December 1, 2025, and December 31, 2025, at 114.5% of the Original Liquidation Preference. Full redemption is permitted after the sixth anniversary.
Material Changes and Governance
The filing details significant changes to the Company's capital structure and governance:
- Board Expansion: The Board of Directors was increased from seven to nine members.
- New Appointments: Srdjan Vukovic (Newlight Partners) was appointed as a Class II Director, and Christopher Wolfe (Bain Capital Insurance) was appointed as a Class I Director.
- Investor Rights: The Preferred Stock holders possess significant protective provisions, including consent rights for changes to the Certificate of Incorporation, issuance of senior securities, indebtedness, asset sales, and Change of Control transactions prior to February 28, 2031.
- Liquidity Period: If the Company fails to redeem shares upon a mandatory redemption trigger, a "Liquidity Period" begins, during which Lead Investors may direct the Company to pursue a liquidity transaction.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance or revenue projections. However, it outlines several material risks and contingencies:
- Dividend Escalation: The dividend rate can increase significantly (up to 20.00% per annum) if the Company enters a "Liquidity Period" or fails to meet payment obligations.
- Warrant Exercise Prices: Tranche B warrants have a floating exercise price based on a 30-day volume-weighted average, with a floor of $2.15 and a cap of $4.00. Tranche C warrants have a fixed exercise price of $5.50.
- Restrictive Covenants: The Company is restricted from incurring new indebtedness, making significant acquisitions, or entering into related-party transactions without Lead Investor consent.
- Change of Control: Any Change of Control prior to 2031 requires the written consent of Morgan Stanley and Bain.
Investor Verification Checklist
- Verify the Company's current liquidity position to determine if the dividend rate will remain at 14.5% or decrease to 13.5%.
- Review the "Certificate of Designations" (Exhibit 3.1) for specific definitions of "Preferred Default" and "Liquidity Period."
- Assess the impact of the 3.0% closing fee on immediate cash flow.
- Monitor the Company's ability to meet the redemption window (Dec 1–31, 2025) for the 50,000 shares at a 14.5% premium.
- Confirm the status of the existing Credit Agreement with Ares Capital Corporation to ensure no cross-defaults are triggered.